Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

Not Recruiting

Trial ID: NCT00227019


This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and overall survival (OS).

Official Title

Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma)

Stanford Investigator(s)

Heather Wakelee
Heather Wakelee

Winston Chen and Phyllis Huang Professor


Inclusion Criteria:

   - Advanced stage NSCLC excluding squamous cell histology with measurable or evaluable

   - Stable brain metastases required, no longer requiring active therapy such as steroid
   medications, which have been previously treated with radiation or surgery or both and
   have been documented to be stable on repeat imaging done at least one month after
   completion of therapy.

   - Prior therapy with one standard doublet front-line regimen for NSCLC (platinum

   - Life expectancy of at least 3 months

   - ECOG Performance status 0-1

   - Age 18 or higher

   - Use of effective means of contraception (men and women) in subjects of child-bearing

   - Ability/willingness to comply with vitamin supplementation including vitamin B 12 and
   folic acid started at least 1 week before first dose of pemetrexed and continued for
   at least 3 weeks after last dose

   - Ability/willingness to take dexamethasone the day before, of and after pemetrexed

   - Drainage of any clinically significant effusion

   - Ability to sign informed consent

Exclusion Criteria:

   - Treatment with more than one prior chemotherapy regimen (unless one regimen was
   stopped for toxicity reasons with a different regimen replacement regimen started
   immediately and patient completed only 4-6 total cycles of first-line treatment. One
   prior regimen (up to 4 cycles) of neoadjuvant or adjuvant therapy for early stage
   disease will also be allowed.

   - Prior treatment with pemetrexed or bevacizumab

   - Prior chemotherapy within 28 days (6 weeks for BCNU, CCNU or mitomycin-C)

   - Current, recent (within 4 weeks of the first infusion of this study), or planned
   participation in any other experimental drug study

   - Concomitant chemotherapy, radiotherapy or investigational agents

   - Uncontrolled effusion (large pleural or peritoneal effusion or small/moderate effusion
   which requires drainage for symptom management)

   - Evidence of bleeding diathesis or coagulopathy

   - Use of anti-coagulant agents including warfarin, heparin, aspirin, NSAIDs

   - Pregnant (positive pregnancy test) or lactating women

   - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
   prior to Day 0, anticipation of need for major surgical procedure during the course of
   the study

   - Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
   prior to day 0

   - Urine protein:creatinine ratio greater than or equal to 1.0 at screening

   - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
   within 6 months prior to Day 0

   - Serious, non-healing wound, ulcer, or bone fracture

   - Lung carcinoma of squamous cell histology or any histology in close proximity to a
   major vessel, or with significant cavitation as assessed by treating investigator in
   consultation with an attending radiologist

   - History of hemoptysis (bright red blood of 1/2 teaspoon or more)

   - Neutrophils < 1.5 x 10^9/ L

   - Hemoglobin <10.0 g/dl

   - Platelets <100 x 10^9/ L

   - Serum glutamic oxaloacetic transaminase (SGOT/ AST) or serum glutamic pyruvic
   transaminase (SGPT/ ALT) > 2.5 times upper limits of normal

   - Creatinine > 1.5 times upper limits of normal

   - Significant co-morbidities including:

      - Blood pressure of greater than 150/100 mmHg

      - Unstable angina

      - New York Heart Association (NYHA) Grade II or greater congestive heart failure

      - History of myocardial infarction within 6 months

      - History of stroke within 6 months

      - Clinically significant peripheral vascular disease

   - Inability to comply with study and/or follow-up procedures


drug: Bevacizumab

drug: Pemetrexed

drug: Vitamin B12

drug: folate

drug: dexamethasone

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Melanie San Pedro-Salcedo

New Trial Alerts